

OPALE - Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Head :Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 01/23/2015 | Version : 2 | ID : 122

General	
Identification	
Detailed name	Survey of the therapeutic management of rheumatoid arthritis in France in 2006
Sign or acronym	OPALE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL 833542 version 11
General Aspects	
Medical area	Rheumatology
Health determinants	Genetic
Others (details)	rheumatoid arthritis
Keywords	Rheumatoid arthritis, epidemiology, DMARD, treatments
Scientific investigator(s) (Contact)	
Name of the director	Bregman
Surname	Bruno
Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	bruno.bregman@bms.com
Unit	Bristol-Myers Squibb
Name of the director	Schmidely
Surname	Nathalie

Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb
Collaborations	
Funding	
Funding status	Private
Details	Bristol-Myers Squibb
Governance of the database	
Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb (BMS)
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Random sampling in clusters
Database objective	
Main objective	Describe the therapeutic practice used by French rheumatologists in patients suffering from rheumatoid arthritis patients, and describe the treatment patterns used, in a general manner and according to the patients' and disease characteristics.

Inclusion criteria	<p>Register Part: M/F ≥ 18 years, with a mild to severe rheumatoid arthritis currently treated or not treated with either symptomatic agents or DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological), seen in rheumatology clinic visit.</p> <p>Detailed Study Part: patients eligible for the register part, currently treated or initiating a first DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological) at the time of inclusion in the study</p>
Population type	
Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p> <p>Great age (80 years and more)</p>
Population covered	Sick population
Gender	<p>Male</p> <p>Woman</p>
Geography area	National
Detail of the geography area	Metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2006
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1600
Data	
Database activity	Data collection completed
Type of data collected	Clinical data

Biological data

Clinical data (detail)

Direct physical measures

Biological data (detail)

ESR, CRP, Rheumatoid factor, HLA DR4, Anti CCP

Presence of a biobank

No

Health parameters studied

Health event/morbidity

Procedures

Data collection method

Paper or electronic form

Participant monitoring

No

Links to administrative sources

No

Promotion and access

Promotion

Link to the document

<http://tinyurl.com/PUBMED-OPALE>

Description

Link to the document

<http://tinyurl.com/HAL-OPALE>

Description

Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only